Overexpression of class III β-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1473-1480

  Aoki, Daisuke ^a   Oda, Yoshinao ^c   Hattori, Satoshi ^g   Taguchi, Ken Ichi ^f   Ohishi, Yoshihiro ^c   Basaki, Yuji ^d,e   Oie, Shinji ^b   Suzuki, Nao ^h   Kono, Suminori ^c   Tsuneyoshi, Masazumi ^c   Ono, Mayumi ^d,e   Yanagawa, Takashi ^g   Kuwano, Michihiko ^e,g  

^a KEIO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g KURUME UNIVERSITY   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; SMALL INTERFERING RNA; STATHMIN; UFT; ANTINEOPLASTIC AGENT; MAP4; TUBULIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CLEAR CELL ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; CHEMISTRY; MIDDLE AGED; MORTALITY; OVARY TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; STATHMIN; TUBULIN;

EID: 63149086677     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1274     Document Type: Article

References (37)

1. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2002;2:1 -17.
2. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents. Int J Oncol 2002; 21:621-8.
3. Maccioni RB, Cambiazo V. Role of microtubule- associated proteins in the control of microtubule assembly. Physiol Rev 1995;75:835-64.
4. Chapin SJ, Lue CM, Yu MT, Bulinski JC. Differential expression of alternatively spliced forms of MAP4: a repertoire of structurally different microtubule-binding domains. Biochemistry 1995;34:2289-301.
5. Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 2003;22:8924-30.
6. AIM E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62: 6864-9.
7. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277: 665-7.
8. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982;94:688-96.
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1 -6.
11. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
12. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the IC0N3 randomised trial. Lancet 2002;360:505-15.
13. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36: 3554-62.
14. Ferlini C, Raspaglio G, Mozzetti S, et al. The secotaxane IDN 5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 2005;65:2397-405.
15. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
16. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
17. Scully RE. Tumors of the ovary and maldeveloped gonads. 3rd series. Washington (DC): Armed Forced Institute of Pathology; 1996. p. 141.
18. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Blaustein A, Kurman RJ. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002. p. 873.
19. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-77.
20. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
21. Sugiyama T Kamura T Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000;88:2584-9.
22. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-91.
23. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
24. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for cancer of the cervix and ovary. Am J Obstet Gynecol 1987;156:236-41.
25. Yuan RH, Jeng YM, Chen HL, et al. Stathmin over- expression cooperates with p53 mutation and osteo- pontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209: 549-58.
26. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11: 155-68.
27. Ohishi Y, Oda Y, Basaki Y, et al. Expression of β-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 2007;105:586-92.
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41 -55.
29. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
30. Akaike H.'A new look as the statistical model identification." IEEE Trans Autom Contr 1974;19:716-23.
31. Sève P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
32. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16:14-9.
33. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 1994;91:11358-62.
34. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
35. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxolresistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
36. Nicoletti Ml, Valoti G, Giannakakou P, et al. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7:2912-22.
37. Zhang CC, Yang JM, Bash-Babula J, et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53- dependent repression of microtubule-associated protein 4. Cancer Res 1999;59:3663-70.